Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site

H. Cui, E. L. Niemitz, J. D. Ravenel, P. Onyango, S. A. Brandenburg, Andrew P Feinberg, A. P. Feinberg

Research output: Contribution to journalArticle

Abstract

Loss of imprinting (LOI) is the most common molecular abnormality in Wilms' tumor (WT), other embryonal cancers, and most other tumor types. LOI in WT involves activation of the normally silent maternal allele of the insulin-like growth factor-H (IGF2) gene, silencing of the normally active maternal allele of the H19 gene, and aberrant methylation of a differentially methylated region (DMR) upstream of the maternal copy of H19. Recently, the transcription factor CTCF, which binds to the H19 DMR, has been implicated in the maintenance of H19 and IGF2 imprinting. Here, we show that mutations in the CTCF gene or in the H19 DMR do not occur at significant frequency in WT, nor is there transcriptional silencing of CTCF. We also confirm that methylation of the H19 DMR in WT with LOI includes the CTCF core consensus site. However, some WTs with normal imprinting of IGF2 also show aberrant methylation of CTCF binding sites, indicating that methylation of these sites is necessary but not sufficient for LOI in WT.

Original languageEnglish (US)
Pages (from-to)4947-4950
Number of pages4
JournalCancer Research
Volume61
Issue number13
StatePublished - Jul 1 2001

Fingerprint

Insulin-Like Growth Factor II
Wilms Tumor
Methylation
Binding Sites
Mutation
Mothers
Alleles
Complement Factor H
Germ Cell and Embryonal Neoplasms
Gene Silencing
Somatomedins
Genes
Transcription Factors
Maintenance
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cui, H., Niemitz, E. L., Ravenel, J. D., Onyango, P., Brandenburg, S. A., Feinberg, A. P., & Feinberg, A. P. (2001). Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Research, 61(13), 4947-4950.

Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. / Cui, H.; Niemitz, E. L.; Ravenel, J. D.; Onyango, P.; Brandenburg, S. A.; Feinberg, Andrew P; Feinberg, A. P.

In: Cancer Research, Vol. 61, No. 13, 01.07.2001, p. 4947-4950.

Research output: Contribution to journalArticle

Cui, H, Niemitz, EL, Ravenel, JD, Onyango, P, Brandenburg, SA, Feinberg, AP & Feinberg, AP 2001, 'Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site', Cancer Research, vol. 61, no. 13, pp. 4947-4950.
Cui, H. ; Niemitz, E. L. ; Ravenel, J. D. ; Onyango, P. ; Brandenburg, S. A. ; Feinberg, Andrew P ; Feinberg, A. P. / Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. In: Cancer Research. 2001 ; Vol. 61, No. 13. pp. 4947-4950.
@article{0aa9261d47fc4e558d210464a42cba14,
title = "Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site",
abstract = "Loss of imprinting (LOI) is the most common molecular abnormality in Wilms' tumor (WT), other embryonal cancers, and most other tumor types. LOI in WT involves activation of the normally silent maternal allele of the insulin-like growth factor-H (IGF2) gene, silencing of the normally active maternal allele of the H19 gene, and aberrant methylation of a differentially methylated region (DMR) upstream of the maternal copy of H19. Recently, the transcription factor CTCF, which binds to the H19 DMR, has been implicated in the maintenance of H19 and IGF2 imprinting. Here, we show that mutations in the CTCF gene or in the H19 DMR do not occur at significant frequency in WT, nor is there transcriptional silencing of CTCF. We also confirm that methylation of the H19 DMR in WT with LOI includes the CTCF core consensus site. However, some WTs with normal imprinting of IGF2 also show aberrant methylation of CTCF binding sites, indicating that methylation of these sites is necessary but not sufficient for LOI in WT.",
author = "H. Cui and Niemitz, {E. L.} and Ravenel, {J. D.} and P. Onyango and Brandenburg, {S. A.} and Feinberg, {Andrew P} and Feinberg, {A. P.}",
year = "2001",
month = "7",
day = "1",
language = "English (US)",
volume = "61",
pages = "4947--4950",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site

AU - Cui, H.

AU - Niemitz, E. L.

AU - Ravenel, J. D.

AU - Onyango, P.

AU - Brandenburg, S. A.

AU - Feinberg, Andrew P

AU - Feinberg, A. P.

PY - 2001/7/1

Y1 - 2001/7/1

N2 - Loss of imprinting (LOI) is the most common molecular abnormality in Wilms' tumor (WT), other embryonal cancers, and most other tumor types. LOI in WT involves activation of the normally silent maternal allele of the insulin-like growth factor-H (IGF2) gene, silencing of the normally active maternal allele of the H19 gene, and aberrant methylation of a differentially methylated region (DMR) upstream of the maternal copy of H19. Recently, the transcription factor CTCF, which binds to the H19 DMR, has been implicated in the maintenance of H19 and IGF2 imprinting. Here, we show that mutations in the CTCF gene or in the H19 DMR do not occur at significant frequency in WT, nor is there transcriptional silencing of CTCF. We also confirm that methylation of the H19 DMR in WT with LOI includes the CTCF core consensus site. However, some WTs with normal imprinting of IGF2 also show aberrant methylation of CTCF binding sites, indicating that methylation of these sites is necessary but not sufficient for LOI in WT.

AB - Loss of imprinting (LOI) is the most common molecular abnormality in Wilms' tumor (WT), other embryonal cancers, and most other tumor types. LOI in WT involves activation of the normally silent maternal allele of the insulin-like growth factor-H (IGF2) gene, silencing of the normally active maternal allele of the H19 gene, and aberrant methylation of a differentially methylated region (DMR) upstream of the maternal copy of H19. Recently, the transcription factor CTCF, which binds to the H19 DMR, has been implicated in the maintenance of H19 and IGF2 imprinting. Here, we show that mutations in the CTCF gene or in the H19 DMR do not occur at significant frequency in WT, nor is there transcriptional silencing of CTCF. We also confirm that methylation of the H19 DMR in WT with LOI includes the CTCF core consensus site. However, some WTs with normal imprinting of IGF2 also show aberrant methylation of CTCF binding sites, indicating that methylation of these sites is necessary but not sufficient for LOI in WT.

UR - http://www.scopus.com/inward/record.url?scp=0035393429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035393429&partnerID=8YFLogxK

M3 - Article

C2 - 11431321

AN - SCOPUS:0035393429

VL - 61

SP - 4947

EP - 4950

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -